We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need. Our initial program is gene therapy for early stage bladder cancer. Inodiftagene vixteplasmid (formerly BC-819) is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC). Inodiftagene has been tested in six clinical trials to date, three of which are in NMIBC. The pivotal development program comprises two registrational trials in NMIBC. The first of these, the Codex Trial, opened in December of 2018 and is recruiting patients now (link to ClinicalTrials.gov). We are located in Cambridge, MA, and in Jerusalem, and are publicly traded on the Nasdaq (NASDAQ: ANCN). Our R&D activities build upon the discovery by Professor Avraham Hochberg, of the Hebrew University of Jerusalem, of the human H19 gene. It has been shown that the gene is expressed in over forty different forms of cancer, including especially bladder cancer, while being quiescent in most normal adult tissues. H19-based therapy is designed to be a highly selective method of killing cancer cells that spares normal bladder tissue. Source
No articles found.
ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdianÂŽ the wor...
ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufac...
We are a commercial-stage biotech company focused on harnessing the inherent biolo...
We are a commercial-stage biotech company focus...
Neopenda is a medical device startup creating solutions that give patients in low-...
Neopenda is a medical device startup creating s...
Spark Therapeutics, a fully integrated company, strives to challenge the inevitabi...
Spark Therapeutics, a fully integrated company,...
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a no...
Bicycle Therapeutics is a clinical-stage biopha...
Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...
Adaptimmune is a leader in TCR T-cell therapy, ...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a no...
Bicycle Therapeutics is a clinical-stage biopha...
Join the National Investor Network and get the latest information with your interests in mind.